Comparative Pharmacology
Head-to-head clinical analysis: PROBUPHINE versus TALWIN NX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROBUPHINE versus TALWIN NX.
PROBUPHINE vs TALWIN NX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Pentazocine is a mixed agonist-antagonist opioid analgesic that acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors. Naloxone is added to prevent intravenous abuse but has no oral bioavailability.
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
1 tablet (pentazocine 50 mg/naloxone 0.5 mg) orally every 3-4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
2-3 hours (terminal) for pentazocine; naloxone half-life 1-1.5 hours. Clinically, duration limited by pentazocine's shorter half-life.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Renal: ~60% as unchanged drug and glucuronide conjugates. Biliary/fecal: ~20% as metabolites. Total: 80% eliminated within 72 hours.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist/Antagonist